Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Daptomycin
Drug ID BADD_D00581
Description Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant _Staphylococcus aureus_ (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE).[A231379, A231384, L32534] Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-terminal 10 amino acids forming an ester-linked ring and the N-terminal tryptophan covalently bonded to decanoic acid.[A231374, L32534] Daptomycin was first discovered in the early 1980s by researchers at Eli Lilly in soil samples from Mount Ararat in Turkey.[A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing scheme reduced side effects while retaining efficacy.[A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Indications and Usage For the treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms.
Marketing Status Prescription; Discontinued
ATC Code J01XX09
DrugBank ID DB00080
KEGG ID D01080
MeSH ID D017576
PubChem ID 16134395
TTD Drug ID D05HPI
NDC Product Code 71288-016; 0143-9378; 0703-0125; 0409-5933; 42513-0015; 16729-434; 67254-515; 73402-111; 31722-102; 0409-0122; 43598-413; 63323-585; 71288-017; 71839-107; 68225-082; 43598-476; 42513-0004; 72572-100; 69097-850; 0409-2757; 60977-145; 68225-052; 25021-174; 67919-012; 57885-0011; 25021-179; 72572-102; 69097-807; 70594-034; 51187-0002; 0409-0120; 67184-0549; 16714-892; 17337-0261; 60505-6229; 67457-813; 63323-871; 0781-3295; 71288-018; 16729-435; 63323-371; 68001-467; 68001-376; 55150-344; 70594-053; 71839-108; 67919-011
Synonyms Daptomycin | Deptomycin | Cubicin | Daptomycin, 9-L beta-Aspartic Acid | Daptomycin, 9 L beta Aspartic Acid | LY-146032 | LY 146032 | LY146032
Chemical Information
Molecular Formula C72H101N17O26
CAS Registry Number 103060-53-3
SMILES CCCCCCCCCC(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(=O)N)C(=O)NC(CC(=O)O)C(=O)NC3C(OC (=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC3=O)CCCN)C C(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=C4N)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypotension24.06.03.0020.001703%
Hypoxia22.02.02.0030.001171%
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.0020.000305%Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
International normalised ratio increased13.01.02.008--
Interstitial lung disease22.01.02.003; 10.02.01.0330.002342%Not Available
Intestinal infarction24.04.08.008; 07.15.02.006--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Jaundice cholestatic09.01.01.0050.000213%Not Available
Lactic acidosis14.01.01.002--Not Available
Laryngeal pain22.02.05.0360.000213%
Leukocytosis01.02.01.0020.000213%
Leukopenia01.02.02.0010.001597%Not Available
Lipase increased13.05.01.0030.000213%
Liver disorder09.01.08.0010.000426%Not Available
Liver function test abnormal13.03.01.0130.000958%Not Available
Loss of consciousness17.02.04.004--Not Available
Lung consolidation22.01.02.0100.000213%Not Available
Lung disorder22.02.07.0010.001703%Not Available
Lung infiltration22.01.02.0040.001384%Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mediastinitis22.09.03.002; 11.01.08.027--
Micturition urgency20.02.02.0060.000213%
Miliaria23.02.03.014--Not Available
Mitral valve incompetence02.07.01.0020.000319%Not Available
Monoparesis17.01.04.011--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 13 Pages